MRI LINAC CONSORTIUM

MRI Linac Consortium


About the MRI-Guided Linac Consortium

The MRI-Linac Consortium will use the Radiosurgery Society’s RSSearch® Patient Registry as a centralized database to collect and track treatment delivery and outcomes of patients treated with the MRI-guided radiotherapy.

The MRI-Linac Consortium will be entering prospective and retrospective data on subjects treated with MRI-guided radiotherapy across multiple tumor sites. Combining data from multiple centers will allow the consortium members to analyze the collective data and publish their findings, which will include many of the first patients treated using this MRI-guided radiotherapy. The Consortium’s initial project will focus on gastrointestinal tumors, specifically pancreas and oligometastatic disease, to explore the clinical utility of MRI-guided radiotherapy on these traditionally difficult to treat indications.

“We are embarking on a unique collaboration with the Radiosurgery Society and ViewRay to advance the science and clinical practice of MRI-guided radiotherapy. The RSSearch Registry provides a comprehensive and flexible system where we can use existing data fields and also customize new ones specific to our study, which will facilitate the analysis of patients treated on MRIdian at various institutions across the globe. Through our contributions to the RSSearch Registry, we hope to demonstrate how MRIdian can achieve substantial clinical benefit for cancer patients.”


Michael Chuong, MD
Director of the MRI-Guided Radiation Therapy Program
Miami Cancer Institute
Member of the ViewRay Gastrointestinal Cancer Consortium

Participating
Centers

Participating Centers

The Radiosurgery Society® is proud to welcome the following MRI-Linac Consortium Centers as participants in the RSSearch® Patient Registry.

  • Acıbadem Maslak Hospital, Istanbul, Turkey
  • Baptist Health, Miami Cancer Institute, Miami, Florida, United States
  • Henry Ford Cancer Institute, Detroit, Michigan, United States

Something About ViewRay

The RSS offers unique opportunities for corporate sponsors to demonstrate their sustained commitment to the success of stereotactic radiotherapies while also gaining broad recognition and exposure to the radiation and surgical communities. With a worldwide membership over 700, presence in 45 countries, and database of over 10,000 domestic and international medical professionals, the RSS offers regular opportunities for you to reinforce your organization’s name recognition and promote the products you manufacture.